Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Comparison of long-term outcome after conventional and accelerated corneal collagen cross-linking in the treatment of progressive keratoconus

Poster Details

First Author: A. Robinet FRANCE

Co Author(s):    D. Touboul   D. Smadja   J. Tellouck              

Abstract Details


To compare the clinical and topographic long-term outcomes after conventional (C-CXL) and accelerated (A-CXL) corneal collagen cross-linking in progressive keratoconic eyes.


Department of Ophthalmology, University Hospital of Bordeaux, France


Data of 737 progressive keratoconic eyes treated by C-CXL or A-CXL between january 2007 and september 2014 were analysed retrospectively. The C-CXL and A-CXL groups respectively received UVA-irradiation with a fluence of 3 mW/cm2, 30 min / 30 mW/cm2, 3 min, with the same overall fluence of 5.4 J/cm2, after 10 min / 20 min of corneal epi-off riboflavin soaking. Uncorrected distance visual acuity, corrected distance visual acuity, corneal pachymetry, topographic maximal keratometry (Kmax) and astigmatism (Ast) changes were assessed and compared in C-CXL and A-CXL groups at baseline, 24 months postoperatively, and at mean last follow-up.


114 eyes treated by C-CXL and 110 eyes treated by A-CXL were analysed. Preoperatively, there were no significant differences between the C-CXL and A-CXL groups in age, sex, Kmax, Ast, central corneal thickness (all p>.05). At 24 months postop, there were no significant differences in ΔUDVA, ΔCDVA, ΔKmax, Δast, and iatrogenic effects prevalence between the groups (all p>.05). At last follow-up (43 months in C-CXL group +/- 9 ; 25 months in A-CXL group +/- 5), topographic parameters had stabilised or improved in 88,7% of C-CXL eyes and in 86,3% of A-CXL eyes.


Conventional and accelerated CXL appear to be effective procedures in halting keratoconus progression with comparable outcome at 24 months postop.

Financial Disclosure:


Back to Poster listing